following a second resubmission
ferric carboxymaltose (Ferinject®) is accepted for restricted use within NHS Scotland.
Indication under review: the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.
SMC restriction: use is restricted to administration by intravenous infusion within the licensed indication but excluding use in patients receiving haemodialysis. The manufacturer’s economic case did not consider the cost-effectiveness of iv bolus administration or use in haemodialysis patients.
Ferric carboxymaltose was superior to oral ferrous sulphate in raising haemoglobin levels in
non-dialysis-dependent patients with chronic kidney disease and iron deficiency anaemia.
Download detailed advice242KB (PDF)
- Medicine name:
- ferric carboxymaltose (Ferinject)
- SMC ID:
- Treatment of iron deficiency when oral preparations are ineffective or cannot be used
- Pharmaceutical company
- Vifor Pharma
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 13 June 2011